Ignat Drozdov
King's College London
Internal medicineEndocrinologyPathologyOncologyTranscriptomeProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyRadionuclide therapyGene clusterSecretionCancer researchBioinformaticsComputational biologyMedicineBiomarker (medicine)Chromogranin ABiologyGastroenterologyCell biology
147Publications
37H-index
5,558Citations
Publications 146
Newest
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 17 authors...
Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter ev...
3 CitationsSource
78 null Introduction: null null Peptide receptor radionuclide therapy (PRRT) is effective in neuroendocrine tumor (NET) management but there are limited tools for monitoring (RECIST) and prediction of tumor response, and for the delineation of side-effects. Accurate monitoring of tumor response is constrained by post-PRRT imaging limitations, and there are no effective blood-genomic assays for hematologic toxicity. We utilized three independent blood-based gene expression assays: a 51-marker gen...
#1Mark KiddH-Index: 66
#1Mark KiddH-Index: 5
Last. Irvin M. ModlinH-Index: 81
view all 4 authors...
BACKGROUND: The NETest is a multi-gene assay comprising 51 circulating neuroendocrine tumor specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight cancer hallmarks or "omes" (apoptome, epigenome, growth factor signalome, metabolome, proliferome, plurome, secretome SSTRome) represent 29 genes. The NETest is an accurate diagnostic (>90%) but its prognostic utility has not been assessed. In this study, we describe expansion of the NET...
4 CitationsSource
#1Mark KiddH-Index: 4
#2Alexandra KitzH-Index: 2
Last. Irvin M. ModlinH-Index: 11
view all 4 authors...
Source
#1Irvin M. ModlinH-Index: 11
#2Mark KiddH-Index: 4
Last. Faidon-Marios LaskaratosH-Index: 7
view all 17 authors...
Source
Source
#1Kambiz RahbarH-Index: 22
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: Neuroendocrine differentiation and the development of an aggressive phenotype are key features of castration-resistant prostate cancer (CRPC) disease. Current blood-based biomarkers cannot detect these treatment-refractory cancer variants. Aims: Evaluate the utility of the NETest, a blood-based 51-marker gene neuroendocrine detection tool, as a CRPC diagnostic and examine which functional gene clusters (hallmarks) differentiate CRPC from PCa. Methods:NETest gene identification in CRP...
Source
#1Kambiz RahbarH-Index: 22
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: There are a paucity of blood-based biomarkers with clinical utility for prostate cancer (PCa). We examined a circulating-free mRNA (27-gene) prostate cancer signature to diagnose PCa. Clinical utility of the assay was then assessed in surgical patients. Methods:Gene identification and validation: Publicly available PCa transcriptome sets (n=5) (E-GEOD-46691, E-GEOD-46602, E-GEOD-62116, E-GEOD-62667, E-GEOD-72220: n=1,159 samples); PCA cell lines (n=7) gene expression in 22Rv1 and E00...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Harry R. Aslanian (Yale University)H-Index: 28
view all 7 authors...
e16079Background: There are few blood-based biomarkers for colorectal cancer (CRC). We report a 13-gene colon cancer circulating-free mRNA to diagnose CRC. Clinical utility was assessed in surgical...
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 8 authors...
3568Background: Peptide receptor radionuclide therapy (PRRT) is an effective therapy for metastatic/inoperable neuroendocrine tumors (NETs). Tools to predict and monitor the efficacy of therapy are...
1 CitationsSource